Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure

The development of protective vaccines against many difficult infectious pathogens will necessitate the induction of effective antibody responses. Here we assess humoral immune responses against two antigens from the blood-stage merozoite of the Plasmodium falciparum human malaria parasite--MSP1 and...

Full description

Bibliographic Details
Main Authors: Biswas, S, Choudhary, P, Elias, S, Miura, K, Milne, K, De Cassan, S, Collins, K, Halstead, F, Bliss, C, Ewer, K, Osier, F, Hodgson, S, Duncan, C, O'Hara, G, Long, C, Hill, A, Draper, S
Format: Journal article
Language:English
Published: Public Library of Science 2014
_version_ 1826291846484066304
author Biswas, S
Choudhary, P
Elias, S
Miura, K
Milne, K
De Cassan, S
Collins, K
Halstead, F
Bliss, C
Ewer, K
Osier, F
Hodgson, S
Duncan, C
O'Hara, G
Long, C
Hill, A
Draper, S
author_facet Biswas, S
Choudhary, P
Elias, S
Miura, K
Milne, K
De Cassan, S
Collins, K
Halstead, F
Bliss, C
Ewer, K
Osier, F
Hodgson, S
Duncan, C
O'Hara, G
Long, C
Hill, A
Draper, S
author_sort Biswas, S
collection OXFORD
description The development of protective vaccines against many difficult infectious pathogens will necessitate the induction of effective antibody responses. Here we assess humoral immune responses against two antigens from the blood-stage merozoite of the Plasmodium falciparum human malaria parasite--MSP1 and AMA1. These antigens were delivered to healthy malaria-naïve adult volunteers in Phase Ia clinical trials using recombinant replication-deficient viral vectors--ChAd63 to prime the immune response and MVA to boost. In subsequent Phase IIa clinical trials, immunized volunteers underwent controlled human malaria infection (CHMI) with P. falciparum to assess vaccine efficacy, whereby all but one volunteer developed low-density blood-stage parasitemia. Here we assess serum antibody responses against both the MSP1 and AMA1 antigens following i) ChAd63-MVA immunization, ii) immunization and CHMI, and iii) primary malaria exposure in the context of CHMI in unimmunized control volunteers. Responses were also assessed in a cohort of naturally-immune Kenyan adults to provide comparison with those induced by a lifetime of natural malaria exposure. Serum antibody responses against MSP1 and AMA1 were characterized in terms of i) total IgG responses before and after CHMI, ii) responses to allelic variants of MSP1 and AMA1, iii) functional growth inhibitory activity (GIA), iv) IgG avidity, and v) isotype responses (IgG1-4, IgA and IgM). These data provide the first in-depth assessment of the quality of adenovirus-MVA vaccine-induced antibody responses in humans, along with assessment of how these responses are modulated by subsequent low-density parasite exposure. Notable differences were observed in qualitative aspects of the human antibody responses against these malaria antigens depending on the means of their induction and/or exposure of the host to the malaria parasite. Given the continued clinical development of viral vectored vaccines for malaria and a range of other diseases targets, these data should help to guide further immuno-monitoring studies of vaccine-induced human antibody responses.
first_indexed 2024-03-07T03:05:36Z
format Journal article
id oxford-uuid:b2676859-c06d-43d2-84b6-8cadbc02375c
institution University of Oxford
language English
last_indexed 2024-03-07T03:05:36Z
publishDate 2014
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:b2676859-c06d-43d2-84b6-8cadbc02375c2022-03-27T04:11:33ZAssessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b2676859-c06d-43d2-84b6-8cadbc02375cEnglishSymplectic Elements at OxfordPublic Library of Science2014Biswas, SChoudhary, PElias, SMiura, KMilne, KDe Cassan, SCollins, KHalstead, FBliss, CEwer, KOsier, FHodgson, SDuncan, CO'Hara, GLong, CHill, ADraper, SThe development of protective vaccines against many difficult infectious pathogens will necessitate the induction of effective antibody responses. Here we assess humoral immune responses against two antigens from the blood-stage merozoite of the Plasmodium falciparum human malaria parasite--MSP1 and AMA1. These antigens were delivered to healthy malaria-naïve adult volunteers in Phase Ia clinical trials using recombinant replication-deficient viral vectors--ChAd63 to prime the immune response and MVA to boost. In subsequent Phase IIa clinical trials, immunized volunteers underwent controlled human malaria infection (CHMI) with P. falciparum to assess vaccine efficacy, whereby all but one volunteer developed low-density blood-stage parasitemia. Here we assess serum antibody responses against both the MSP1 and AMA1 antigens following i) ChAd63-MVA immunization, ii) immunization and CHMI, and iii) primary malaria exposure in the context of CHMI in unimmunized control volunteers. Responses were also assessed in a cohort of naturally-immune Kenyan adults to provide comparison with those induced by a lifetime of natural malaria exposure. Serum antibody responses against MSP1 and AMA1 were characterized in terms of i) total IgG responses before and after CHMI, ii) responses to allelic variants of MSP1 and AMA1, iii) functional growth inhibitory activity (GIA), iv) IgG avidity, and v) isotype responses (IgG1-4, IgA and IgM). These data provide the first in-depth assessment of the quality of adenovirus-MVA vaccine-induced antibody responses in humans, along with assessment of how these responses are modulated by subsequent low-density parasite exposure. Notable differences were observed in qualitative aspects of the human antibody responses against these malaria antigens depending on the means of their induction and/or exposure of the host to the malaria parasite. Given the continued clinical development of viral vectored vaccines for malaria and a range of other diseases targets, these data should help to guide further immuno-monitoring studies of vaccine-induced human antibody responses.
spellingShingle Biswas, S
Choudhary, P
Elias, S
Miura, K
Milne, K
De Cassan, S
Collins, K
Halstead, F
Bliss, C
Ewer, K
Osier, F
Hodgson, S
Duncan, C
O'Hara, G
Long, C
Hill, A
Draper, S
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
title Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
title_full Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
title_fullStr Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
title_full_unstemmed Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
title_short Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
title_sort assessment of humoral immune responses to blood stage malaria antigens following chad63 mva immunization controlled human malaria infection and natural exposure
work_keys_str_mv AT biswass assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT choudharyp assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT eliass assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT miurak assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT milnek assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT decassans assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT collinsk assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT halsteadf assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT blissc assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT ewerk assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT osierf assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT hodgsons assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT duncanc assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT oharag assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT longc assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT hilla assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure
AT drapers assessmentofhumoralimmuneresponsestobloodstagemalariaantigensfollowingchad63mvaimmunizationcontrolledhumanmalariainfectionandnaturalexposure